- Investing.com
Krystal Biotech, Inc., a commercial-stage biotechnology company, discovers, develops, manufactures, and commercializes genetic medicines to treat diseases with high unmet medical needs in the United States. The company commercializes VYJUVEK (beremagene geperpavec-svdt, or B-VEC) for the treatment of dystrophic epidermolysis bullosa (DEB). It also develops KB105, which is in Phase 1/2 clinical trials for treating patients with deficient autosomal recessive congenital ichthyosis; KB104 for treating netherton syndrome; KB407 that is in Phase 1 clinical trials for treating cystic fibrosis; KB707 that is in Phase 1/2 clinical trials for the treatment of anti-PD-1 relapsed/refractory; KB408, which is in Phase 1 clinical trials for treating Alpha-1 antitrypsin deficiency; and KB301 that is in Phase 2 clinical trials for treating aesthetic skin conditions, as well as in open label study with ophthalmic B-VEC for treating for ocular complications of deb. Krystal Biotech, Inc. was founded in 2016 and is headquartered in Pittsburgh, Pennsylvania.
Metrics to compare | 1KRYS | Sector Sector - Average of metrics from a broad group of related sector companies | Relationship Relationship1KRYSPeersSector | |
---|---|---|---|---|
P/E Ratio | 35.8x | −4.1x | −0.5x | |
PEG Ratio | 0.32 | −0.20 | 0.00 | |
Price/Book | 4.5x | 1.9x | 2.6x | |
Price / LTM Sales | 13.3x | 9.4x | 3.2x | |
Upside (Analyst Target) | - | 72.2% | 41.2% | |
Fair Value Upside | Unlock | 15.5% | 6.2% | Unlock |